Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Am J Hematol
3 Ann Hematol
8 Blood
2 Bone Marrow Transplant
1 Cancer
1 Cancer Chemother Pharmacol
1 Eur J Haematol
1 Int J Hematol
5 Leuk Lymphoma
4 Leuk Res
3 Leukemia
1 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Hematol

  1. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.

    Ann Hematol

  2. ALRAWASHDH N, Sweasy J, Erstad B, McBride A, et al
    Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04600.
    PubMed         Abstract available

  3. ELNAIR R, Ellithi M, Kallam A, Shostrom V, et al
    Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04603.
    PubMed         Abstract available

  4. KONG J, Qin YZ, Zhao XS, Hou Y, et al
    Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Ann Hematol. 2021 Jul 19. pii: 10.1007/s00277-021-04606.
    PubMed         Abstract available


  5. HOFF FW, van Dijk AD, Qiu Y, Ruvolo PP, et al
    Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
    Blood. 2021;137:1050-1060.
    PubMed         Abstract available

  6. WILLIER S, Rothamel P, Hastreiter M, Wilhelm J, et al
    CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
    Blood. 2021;137:1037-1049.
    PubMed         Abstract available

  7. MICHALLET AS, Letestu R, Le Garff-Tavernier M, Aanei C, et al
    A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.
    Blood. 2021;137:1019-1023.
    PubMed         Abstract available

  8. STAUBER J, Greally J, Steidl U
    Preleukemic and Leukemic Evolution at the Stem Cell Level.
    Blood. 2020 Dec 4. pii: 474417. doi: 10.1182/blood.2019004397.
    PubMed         Abstract available

    The essential reading list for AML: the m6A transcripts.
    Blood. 2021;138:6-7.

  10. KUTSCH N
    CLL-IPI: valid in the era of oral inhibitors?
    Blood. 2021;138:106-107.

  11. BUTLER M, van Ingen Schenau DS, Yu J, Jenni S, et al
    BTK inhibition sensitizes Acute Lymphoblastic Leukemia to asparaginase by suppressing the Amino Acid Response pathway.
    Blood. 2021 Jul 19. pii: 476421. doi: 10.1182/blood.2021011787.
    PubMed         Abstract available

  12. JETANI H, Navarro-Bailon A, Maucher M, Frenz S, et al
    Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML).
    Blood. 2021 Jul 21. pii: 476427. doi: 10.1182/blood.2020009192.
    PubMed         Abstract available

    Bone Marrow Transplant

  13. ZUCENKA A, Vaitekenaite V, Maneikis K, Davainis L, et al
    Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Jul 17. pii: 10.1038/s41409-021-01416.
    PubMed         Abstract available

  14. KONUMA T, Kondo T, Masuko M, Shimizu H, et al
    Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission.
    Bone Marrow Transplant. 2021 Jul 16. pii: 10.1038/s41409-021-01409.
    PubMed         Abstract available


  15. Erratum to "Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL113
    Cancer. 2021 Jul 22. doi: 10.1002/cncr.33597.

    Cancer Chemother Pharmacol

  16. GOTO H, Yoshino Y, Ito M, Nagai J, et al
    Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 Jul 18. pii: 10.1007/s00280-021-04321.

    Eur J Haematol

  17. GRIFFIN JD, Song Y, Yang H, Freimark J, et al
    Posttransplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13692.
    PubMed         Abstract available

    Int J Hematol

  18. SATOH T, Kayano H, Watanabe A, Ohta A, et al
    Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report.
    Int J Hematol. 2021 Jul 16. pii: 10.1007/s12185-021-03189.
    PubMed         Abstract available

    Leuk Lymphoma

  19. WITTMANN DAYAGI T, Sherman G, Bielorai B, Adam E, et al
    Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells.
    Leuk Lymphoma. 2021;62:1692-1701.
    PubMed         Abstract available

  20. JINDAL N, Lad DP, Malhotra P, Prakash G, et al
    Randomized controlled trial of individualized, low dose, fixed duration lenalidomide maintenance versus observation after frontline chemo-immunotherapy in CLL.
    Leuk Lymphoma. 2021;62:1674-1681.
    PubMed         Abstract available

  21. DUNN KA, Forbrigger Z, Connors J, Rahman M, et al
    Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021 Jul 19:1-12. doi: 10.1080/10428194.2021.1953006.
    PubMed         Abstract available

  22. WEBSTER JA, Yogarajah M, Zahurak M, Symons H, et al
    A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic
    Leuk Lymphoma. 2021 Jul 21:1-11. doi: 10.1080/10428194.2021.1948029.
    PubMed         Abstract available

  23. PALANQUES-PASTOR T, Megias-Vericat JE, Martinez P, Lopez Lorenzo JL, et al
    Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group.
    Leuk Lymphoma. 2021 Jul 22:1-11. doi: 10.1080/10428194.2021.1948031.
    PubMed         Abstract available

    Leuk Res

  24. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
    Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
    Leuk Res. 2021;104:106541.

  25. ALI H, Salhotra A, Stein AS, Nakamura R, et al
    Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
    Leuk Res. 2021;104:106579.

  26. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
    Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
    Leuk Res. 2021;110:106666.
    PubMed         Abstract available

  27. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
    Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106665.
    PubMed         Abstract available


  28. VAN DER WERF I, Wojtuszkiewicz A, Yao H, Sciarrillo R, et al
    Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia.
    Leukemia. 2021 Jul 8. pii: 10.1038/s41375-021-01340.

  29. KLEINSTERN G, Weinberg JB, Parikh SA, Braggio E, et al
    Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01344.
    PubMed         Abstract available

  30. ZHAO XY, Xu ZL, Mo XD, Chen YH, et al
    Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01351.

    PLoS One

  31. KARAMI K, Akbari M, Moradi MT, Soleymani B, et al
    Survival prognostic factors in patients with acute myeloid leukemia using machine learning techniques.
    PLoS One. 2021;16:e0254976.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  32. PAN L, Hong C, Chan LN, Xiao G, et al
    PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.